Table 2 Outcomes in the pre-pandemic (PP) and pandemic (P) groups. Values are numbers (percentages) unless stated otherwise
PP (n = 108) | P (n = 252) | Overall (n = 360) | p-value | |
|---|---|---|---|---|
Primary outcome | ||||
PUs incidence, n (%) | 11 (10.2) | 55 (21.8) | 66 (18.3) | 0.009 |
PUs anatomic location | 0.004 | |||
Sacrum, n (%) | 10 (90.9) | 21 (38.2) | 31 (47.0) | |
Heel, n (%) | 0 (0) | 17 (30.9) | 17 (25.8) | |
Other locations, n (%) | 1 (9.1) | 17 (30.9) | 18 (27.2) | |
PUs stage | 0.837 | |||
Stage I, n (%) | 3 (30.0) | 18 (33.3) | 21 (32.8) | |
Stage II, n (%) | 7 (70.0) | 36 (67.7) | 43 (67.2) | |
Median (IQR) time to PU development (days) | 6 (3) | 4.5 (6) | 4.5 (4.7) | 0.587 |
Secondary outcomes | ||||
First standing, n (%) | 0.37 | |||
≤ 2 days | 59 (54.6) | 144 (57.1) | 203 (56.4) | |
> 2 days | 44 (40.7) | 88 (34.9) | 132 (36.7) | |
Never | 5 (4.7) | 20 (8.0) | 25 (6.9) | |
Median (IQR) time to first standing (days) | 2.0 (1.5) | 2.0 (2.0) | 2.0 (2.0) | 0.34 |
First Ambulation, n (%) | 0.65 | |||
≤ 3 days | 57 (52.8) | 120 (47.6) | 177 (49.2) | |
> 3 days | 28 (25.9) | 75 (29.8) | 103 (28.6) | |
Never | 23 (21.3) | 57 (22.6) | 80 (22.2) | |
Median (IQR) time to first ambulation (days) | 3 (2) | 3 (2) | 3 (2) | 0.59 |